<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: proposed merger with", fill: "#004242"},
{source: "4: proposed merger with", target: "4: Caliper Life Sciences Inc", fill: "#004242"},
{source: "4: proposed merger with", target: "16: uncertainty may adversely affect", fill: "#af4035"},
{source: "16: uncertainty may adversely affect", target: "16: key management marketing technical", fill: "#af4035"},
{source: "16: key management marketing technical", target: "16: manufacturing administrative sales", fill: "#af4035"},
{source: "16: uncertainty may adversely affect", target: "17: accumulated deficit", fill: "#800080"},
{source: "17: accumulated deficit", target: "17: December ", fill: "#800080"},
{source: "17: December ", target: "17: profitability", fill: "#800080"},
{source: "17: accumulated deficit", target: "28: technologies", fill: "#f2003c"},
{source: "28: technologies", target: "28: technology", fill: "#f2003c"},
{source: "28: technology", target: "28: relatively", fill: "#f2003c"},
{source: "28: relatively", target: "28: institutions using", fill: "#f2003c"},
{source: "28: technologies", target: "36: early stage", fill: "#fe2712"},
{source: "36: early stage", target: "36: commercialization", fill: "#fe2712"},
{source: "36: commercialization", target: "36: operations", fill: "#fe2712"},
{source: "36: operations", target: "36: evaluation", fill: "#fe2712"},
{source: "36: evaluation", target: "36: future growth prospects", fill: "#fe2712"},
{source: "36: future growth prospects", target: "36: difficult", fill: "#fe2712"},
{source: "36: early stage", target: "46: typically involve", fill: "#f4c430"},
{source: "46: typically involve", target: "46: significant scientific", fill: "#f4c430"},
{source: "46: significant scientific", target: "46: evaluation", fill: "#f4c430"},
{source: "46: evaluation", target: "46: commitment", fill: "#f4c430"},
{source: "46: commitment", target: "46: capital by customers", fill: "#f4c430"},
{source: "46: typically involve", target: "47: Accordingly ", fill: "#704241"},
{source: "47: Accordingly ", target: "47: significant", fill: "#704241"},
{source: "47: significant", target: "47: budgetary constraints", fill: "#704241"},
{source: "47: budgetary constraints", target: "47: internal acceptance reviews", fill: "#704241"},
{source: "47: Accordingly ", target: "51: recognition", fill: "#800000"},
{source: "51: recognition", target: "51: of Contents ", fill: "#800000"},
{source: "51: of Contents ", target: "51: manufacture", fill: "#800000"},
{source: "51: manufacture", target: "51: quarterly revenues", fill: "#800000"},
{source: "51: recognition", target: "START_HERE", fill: "#800000"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Caliper_Life_Sciences">Caliper Life Sciences</a></td>
      <td>Caliper, A PerkinElmer Company produces  products and services for life sciences research. The firm, founded in 1995,  is based in Hopkinton, Massachusetts with direct sales, service and application-support operations in countries around the globe.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Algebraically_closed_field">Algebraically closed field</a></td>
      <td>In mathematics, a field F is algebraically closed if every non-constant polynomial in F[x] (the univariate polynomial ring with coefficients in F) has a root in F.\n\n\n== Examples ==\nAs an example, the field of real numbers is not algebraically closed, because the polynomial equation x2 + 1 = 0  has no solution in real numbers, even though all its coefficients (1 and 0) are real.  The same argument proves that no subfield of the real field is algebraically closed; in particular, the field of rational numbers is not algebraically closed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alberta_Genealogical_Society">Alberta Genealogical Society</a></td>
      <td>The Alberta Genealogical Society (AGS) is a non-profit educational organization headquartered at 14315 118 Ave, Edmonton, Alberta, Canada. Founded in 1970, AGS is one of the largest genealogical societies in Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porcelain_manufacturing_companies_in_Europe">Porcelain manufacturing companies in Europe</a></td>
      <td>Porcelain manufacturing companies are firms which manufacture porcelain.\n\n\n== European porcelain manufacturers before the 18th century ==\nThe table below lists European manufacturers of porcelain established before the 18th century.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>XENOGEN CORP      Item 1A Risk Factors        In addition to the forward-looking statements discussed in this report, we     <font color="blue">also provide</font> the <font color="blue">following cautionary</font> discussion of risks, uncertainties and     <font color="blue">possibly inaccurate <font color="blue">assumption</font>s relevant</font> to our business</td>
    </tr>
    <tr>
      <td>These items are     factors that we believe could cause our actual results to <font color="blue">differ <font color="blue">materially</font></font>     from expected and historical results</td>
    </tr>
    <tr>
      <td>Other <font color="blue">factors also could <font color="blue">adversely</font></font>     <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">proposed <font color="blue">merger with</font></font> Caliper Life Sciences, Inc</td>
    </tr>
    <tr>
      <td>is not consummated,     our stock price, business and <font color="blue"><font color="blue">operations</font> could</font> be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">February </font></font>10, 2006, we <font color="blue">entered into</font> a <font color="blue">definitive</font> <font color="blue">Agreement and Plan </font>of     Merger  with  Caliper  Life Sciences, Inc</td>
    </tr>
    <tr>
      <td>and its subsidiary, <font color="blue">Caliper     </font>Holdings, Inc, pursuant to which we will be <font color="blue">merged with</font> and into <font color="blue">Caliper     </font>Holdings and become a wholly-owned subsidiary of Caliper</td>
    </tr>
    <tr>
      <td>A copy of the     <font color="blue">merger <font color="blue">agreement</font></font> and other <font color="blue">documents</font> relating to the merger are <font color="blue">attached as</font>     exhibits to the <font color="blue">Current Report </font>on Form 8-K that we                                           17     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font><font color="blue">filed with</font> the <font color="blue">Securities and Exchange Commission </font>on <font color="blue">February </font>16, 2006</td>
    </tr>
    <tr>
      <td>Our     Board of Directors has approved the merger and the <font color="blue">merger <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>In     March 2006, <font color="blue">Caliper and Xenogen </font>will file a <font color="blue">registration statement on</font> Form     S-4 and a notice of <font color="blue">special meeting</font> of <font color="blue">stockholders</font> and <font color="blue">definitive</font> proxy     statement for the <font color="blue">special meeting</font> of <font color="blue">stockholders</font> pursuant to which we will     ask our <font color="blue">stockholders</font> to adopt and approve the <font color="blue">merger <font color="blue">agreement</font></font> and the     merger</td>
    </tr>
    <tr>
      <td>The <font color="blue">obligations</font> of <font color="blue">Caliper and Xenogen </font>to effect the merger are subject to a     number  of  <font color="blue">conditions</font>,  including <font color="blue">approval by</font> the Xenogen and <font color="blue">Caliper     </font><font color="blue">stockholders</font>, and the <font color="blue">merger may</font> not occur</td>
    </tr>
    <tr>
      <td>If the merger is not consummated     for any reason, we may be subject to a number of material risks, including     the following:           •   we may be required to pay Caliper a <font color="blue">termination</font> fee of dlra3dtta1 million;           •   the price of our common stock may decline to the extent that the     <font color="blue">current <font color="blue">market price</font></font> of our <font color="blue">common stock reflects</font> an <font color="blue">assumption</font> that the     <font color="blue">merger will</font> be completed; and           •   we must pay our <font color="blue">accrued costs</font> related to the merger, such as legal,     <font color="blue">accounting</font> and certain financial advisory fees, even if the merger is not     completed</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">customers may</font>, in response to the <font color="blue">announcement</font> of the     merger,  delay or <font color="blue">defer purchasing decisions</font></td>
    </tr>
    <tr>
      <td>Any delay or deferral in     <font color="blue">purchasing decisions by</font> our <font color="blue">customers would</font> have a material adverse effect     on our business, <font color="blue">regardless</font> of whether or not the merger is ultimately     completed</td>
    </tr>
    <tr>
      <td>Similarly, our current and <font color="blue">prospective employees may</font> experience <font color="blue">uncertainty</font>     about their <font color="blue">future role with</font> Caliper until Caliper’s <font color="blue">strategies with</font> regard     to us are announced or executed</td>
    </tr>
    <tr>
      <td>This <font color="blue">uncertainty</font> may <font color="blue"><font color="blue">adversely</font> affect</font> our     ability  to  attract  and retain key <font color="blue">management</font>, marketing, technical,     <font color="blue">manufacturing</font>, administrative, sales and other personnel</td>
    </tr>
    <tr>
      <td>We have a history of losses and an <font color="blue">accumulated deficit</font> of dlra186dtta3 million as     of <font color="blue">December </font>31, 2005, and we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred <font color="blue">significant</font> net losses every year since</font> our inception</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of     dlra186dtta3 million</td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">profitability</font>, we will need to generate and     <font color="blue">sustain <font color="blue">substantially</font> higher revenue than</font> we have to date, while achieving     <font color="blue">reasonable costs</font> and <font color="blue">expense levels</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">generate enough</font>     revenue to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may not achieve or maintain reasonable     costs and <font color="blue">expense levels</font></td>
    </tr>
    <tr>
      <td>Even if we become profitable, we may not be able     to sustain or increase <font color="blue">profitability</font> on a quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>If we     fail to achieve <font color="blue">profitability</font> within the timeframe expected <font color="blue">by securities</font>     analysts or investors, the <font color="blue">market price</font> of our <font color="blue">common stock will likely</font>     decline</td>
    </tr>
    <tr>
      <td>If our products and services do not <font color="blue">become widely used by <font color="blue">pharmaceutical</font></font>,     bio<font color="blue">technology</font>, biomedical and <font color="blue">chemical <font color="blue">researchers</font></font>, it is unlikely that we     <font color="blue">will ever become profitable</font></td>
    </tr>
    <tr>
      <td>Pharmaceutical, bio<font color="blue">technology</font>, biomedical and <font color="blue">chemical <font color="blue">researchers</font></font> have     <font color="blue"><font color="blue">historically</font> conducted</font> in <font color="blue"><font color="blue">vivo <font color="blue">biological assessment</font></font> using</font> a variety of     <font color="blue">technologies</font>,  including a variety of <font color="blue">animal models</font></td>
    </tr>
    <tr>
      <td>Compared to these     <font color="blue">technologies</font>, our <font color="blue">technology</font> is <font color="blue">relatively</font> new, and the number of companies     and <font color="blue">institutions using</font> our <font color="blue">technology</font> is <font color="blue">relatively</font> limited</td>
    </tr>
    <tr>
      <td>The commercial     success of our <font color="blue">products will depend upon</font> the <font color="blue">widespread adoption</font> of our     <font color="blue">technology</font> as a <font color="blue">preferred method</font> to perform in <font color="blue">vivo <font color="blue">biological assessment</font></font></td>
    </tr>
    <tr>
      <td>In order to be successful, our <font color="blue">products must meet</font> the technical and cost     <font color="blue">requirements</font> for in <font color="blue">vivo <font color="blue">biological assessment</font></font> within the <font color="blue">life sciences</font>     industry</td>
    </tr>
    <tr>
      <td><font color="blue">Widespread  </font>market  <font color="blue">acceptance will depend on</font> many factors,     including:           •   the <font color="blue">willingness</font> and ability of <font color="blue">researchers</font> and <font color="blue">prospective customers</font>     to adopt new <font color="blue">technologies</font>;                                           18     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>  •   our ability to <font color="blue">convince prospective strategic partners</font> and customers     that our <font color="blue">technology</font> is an <font color="blue">attractive alternative</font> to other methods of in vivo     <font color="blue">biological assessment</font>;           •   our customers’ perception that our products can <font color="blue">help accelerate</font>     efforts and <font color="blue">reduce costs</font> in <font color="blue">drug <font color="blue">development</font></font>; and           •   our ability to sell and <font color="blue">service sufficient quantities</font> of our products</td>
    </tr>
    <tr>
      <td>Additionally, to our knowledge, only one of our <font color="blue">drug <font color="blue">development</font></font> customers     has  used our imaging <font color="blue">technology</font> to submit an <font color="blue">investigational</font> new drug     <font color="blue">application</font>, or IND, to the Food and Drug Administration, or FDA, and no     drugs have <font color="blue">been approved</font> to <font color="blue">date using</font> our imaging <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>As a result,     our  ability  to assist the <font color="blue">drug <font color="blue">development</font></font> process in leading to the     approval of <font color="blue">drugs with commercial potential</font> has yet to be <font color="blue">fully proven</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">commercial advantages</font> are not realized from the use of in <font color="blue">vivo <font color="blue">biophotonic</font></font>     imaging, our <font color="blue">existing customers could stop using</font> our products, and we could     have  <font color="blue"><font color="blue">difficult</font>y</font>  <font color="blue">attracting <font color="blue">new customers</font></font></td>
    </tr>
    <tr>
      <td>Because of these and other     factors, our <font color="blue">products may</font> not <font color="blue">gain widespread market acceptance</font> or become     the industry standard for in <font color="blue">vivo <font color="blue">biological assessment</font></font></td>
    </tr>
    <tr>
      <td>As a company in the <font color="blue">early stage</font> of <font color="blue">commercialization</font>, our limited history of     <font color="blue">operations</font> makes <font color="blue">evaluation</font> of our business and <font color="blue">future growth prospects</font>     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>We  have  had a limited operating history and are at an <font color="blue">early stage</font> of     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>While we sold our first IVIS^® Imaging Systems and     <font color="blue">entered into</font> our first commercial license in 2000, we did not begin to sell     our products and services in commercial quantities until 2002</td>
    </tr>
    <tr>
      <td>Our in vivo     <font color="blue">biophotonic</font> imaging <font color="blue">technology</font> is a <font color="blue">relatively</font> new <font color="blue">technology</font> that has not     yet achieved <font color="blue">widespread adoption</font></td>
    </tr>
    <tr>
      <td>To date, we have <font color="blue">generated revenues</font> of     dlra16dtta0 million in 2002, dlra20dtta1 million in 2003, dlra30dtta9 million in 2004 and     dlra39dtta7 million in 2005</td>
    </tr>
    <tr>
      <td>We  do  not  have enough experience in selling our <font color="blue">products at</font> a level     <font color="blue">consistent with broad market acceptance</font> and to know whether we can do so and     generate a profit</td>
    </tr>
    <tr>
      <td>As a result of these factors, it is <font color="blue">difficult</font> to evaluate     our prospects, and our future success is more uncertain than if we had a     longer or more proven history of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future revenue</font> is unpredictable and could cause our operating results to     <font color="blue">fluctuate <font color="blue">significant</font>ly from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>In particular, our operating results in     the first and <font color="blue">third quarters</font> have <font color="blue"><font color="blue">historically</font> been lower than</font> those in the     second  and  <font color="blue">fourth quarters due</font> to the decision-making process of our     <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>The sale of many of our products, including our IVIS Imaging     Systems and related Bioware, <font color="blue">typically involve</font> a <font color="blue"><font color="blue">significant</font> scientific</font>     <font color="blue">evaluation</font> and <font color="blue">commitment</font> of <font color="blue">capital by customers</font></td>
    </tr>
    <tr>
      <td>Accordingly, the initial     <font color="blue">sales cycles</font> of many of our products are lengthy and subject to a number of     <font color="blue">significant</font>  risks  that  are beyond our control, including customers’     <font color="blue">budgetary constraints</font> and <font color="blue">internal acceptance reviews</font></td>
    </tr>
    <tr>
      <td>As a result of this     lengthy  and  unpredictable  sales  cycle,  our operating results have     <font color="blue">historically</font> fluctuated <font color="blue">significant</font>ly from quarter to quarter, and we expect     this  trend to continue</td>
    </tr>
    <tr>
      <td>In addition, a large portion of our expenses,     including expenses for our Alameda, California and Cranbury, New Jersey     facilities, equipment and personnel, are <font color="blue">relatively</font> fixed</td>
    </tr>
    <tr>
      <td>Historically,     <font color="blue">customer <font color="blue">buying patterns</font></font> and our <font color="blue">revenue growth</font> have caused a substantial     portion of our revenues to occur in the last month of the quarter</td>
    </tr>
    <tr>
      <td>Delays in     the receipt of orders, our <font color="blue">recognition</font> of product                                           19     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>or service revenue or the <font color="blue">manufacture</font> of product near the end of the quarter     could cause <font color="blue">quarterly revenues</font> to fall short of anticipated levels</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>our operating expenses are <font color="blue">based on</font> anticipated <font color="blue">revenue levels</font> and a high     percentage of our expenses are <font color="blue">relatively</font> fixed, less than anticipated     revenues  for a <font color="blue">quarter could</font> have a <font color="blue">significant</font> adverse <font color="blue">impact on</font> our     operating results</td>
    </tr>
    <tr>
      <td>Accordingly, if our <font color="blue">revenue declines</font> or does not increase     as  we  anticipate, we might not be able to <font color="blue">correspondingly reduce</font> our     operating expenses in a <font color="blue">timely enough manner</font> to <font color="blue">avoid incurring additional</font>     losses</td>
    </tr>
    <tr>
      <td>Our failure to achieve our anticipated level of <font color="blue">revenue could</font>     <font color="blue">significant</font>ly harm our operating results for a <font color="blue">particular fiscal period</font></td>
    </tr>
    <tr>
      <td>The following are <font color="blue">among additional factors</font> that could cause our operating     results to fluctuate <font color="blue">significant</font>ly from period to period:           •   changes in the demand for, and pricing of, our products and services;           •   the length of our <font color="blue">sales cycles</font> and <font color="blue">buying patterns</font> of our customers,     which may cause a decrease in our operating results for a <font color="blue">quarterly period</font>;           •   the nature, pricing and timing of other products and <font color="blue">services provided</font>     by us or our <font color="blue">competitors</font>;           •   changes in our <font color="blue">long term custom animal production contracts</font> and other     <font color="blue">renewable contracts</font>, including licenses;           •   our ability to obtain <font color="blue">key <font color="blue">components</font></font> for our <font color="blue"><font color="blue">imaging system</font>s</font> and     <font color="blue">manufacture</font> and <font color="blue">install them on</font> a <font color="blue">timely basis</font> to meet demand;           •   changes in the research and <font color="blue">development</font> budgets of our customers;           •   acquisition, licensing and other costs related to the expansion of our     <font color="blue">operations</font>;           •   the timing of milestones, licensing and other <font color="blue">payments under</font> the terms     of our license <font color="blue"><font color="blue">agreement</font>s</font>, commercial <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> pursuant</font> to     which others license <font color="blue">technology</font> to us;           •   expenses related to our commercial and <font color="blue">patent <font color="blue">infringement</font> <font color="blue">litigation</font></font>     with <font color="blue">AntiCancer </font>and other <font color="blue">litigation</font> in which we <font color="blue">may become involved</font>; and           •   expenses related to, and the results of, <font color="blue">patent filings</font> and other     <font color="blue">proceedings</font> relating to <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">possibility</font> of <font color="blue">fluctuations</font> in our revenue and expenses, we     believe that quarter to quarter or <font color="blue">annual comparisons</font> of our operating     results are not a good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font> or non-renewal of a large contract or the loss of, or a     <font color="blue">significant</font> reduction in, sales to any of our <font color="blue">significant</font> customers could     harm our operating results</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally sell</font> our products and <font color="blue">often provide</font> our <font color="blue">services pursuant</font> to     <font color="blue"><font color="blue">agreement</font>s</font> that are <font color="blue">renewable on</font> an <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>Failure to renew or the     <font color="blue">cancellation</font> of these <font color="blue"><font color="blue">agreement</font>s</font> by any one of our <font color="blue">significant</font> customers,     which include Pfizer Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">affiliates</font> of Novartis, could result in a     <font color="blue">significant</font> loss of revenue</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently derive</font>, and we expect to continue     to derive, a large percentage of our <font color="blue">total revenue from</font> a <font color="blue">relatively</font> small     number of customers</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">customers terminates</font> or <font color="blue">substantially</font>     <font color="blue">diminishes</font>                                           20     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>its <font color="blue">relationship with us</font>, our <font color="blue">revenue could</font> decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td><font color="blue">Revenue     </font><font color="blue">concentration among</font> our largest customers is as follows:           •   our <font color="blue">ten largest customers accounted</font> for <font color="blue">approximately</font> 32dtta8prca, 41prca and     53prca of our revenue for the years ended <font color="blue">December </font>31, 2005, 2004 and 2003,     <font color="blue">respectively</font>; and           •   our largest and <font color="blue">second largest customers accounted</font> for <font color="blue">approximately</font>     12prca and 5prca of our revenue for the year ended <font color="blue">December </font>31, 2005, 16prca and 7prca     of our revenue for the year ended <font color="blue">December </font>31, 2004, and 21prca and 11prca of our     revenue for the year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">significant</font> revenue from any of our <font color="blue">significant</font> customers could     <font color="blue">negatively impact</font> our results of <font color="blue">operations</font> or limit our ability to execute     our strategy</td>
    </tr>
    <tr>
      <td>We may not fully realize our revenue under long-term contracts, which could     harm our business and result in <font color="blue">higher losses than</font> anticipated</td>
    </tr>
    <tr>
      <td>We have long-term contracts for custom animal production and/or phenotyping     <font color="blue">services with two customers</font> that are <font color="blue">renewed annually</font> and are expected to     generate <font color="blue">future revenue</font>s</td>
    </tr>
    <tr>
      <td>These two long-term contracts may not be renewed     annually and may be <font color="blue">terminated at</font> any time during their terms</td>
    </tr>
    <tr>
      <td>In addition,     we may not be able to maintain our <font color="blue">sublicensed rights under certain patents</font>     relating to these contracts</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">meet customer</font> demand</font>, it <font color="blue">would <font color="blue">adversely</font> impact</font> our     financial results and restrict our <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>To  be  successful,  we  must  <font color="blue">manufacture</font> our <font color="blue">IVIS Imaging Systems </font>in     substantial  quantities  at  acceptable costs</td>
    </tr>
    <tr>
      <td>If we do not succeed in     <font color="blue"><font color="blue">manufacturing</font> sufficient quantities</font> of our <font color="blue"><font color="blue">imaging system</font>s</font> to <font color="blue">meet customer</font>     demand, we <font color="blue">could lose customers</font> and fail to acquire <font color="blue">new customers</font>, if they     choose a competitor’s product because our <font color="blue">imaging system</font> is not available</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing  </font>demand  since  the  launch  of our <font color="blue">IVIS Imaging System </font>has     <font color="blue">necessitated</font> an increase in our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capacity</font></font></td>
    </tr>
    <tr>
      <td>We believe our     current <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capacity</font></font> in Alameda, California is sufficient to meet     our current and forecasted demand through 2006, and we are in the planning     stages for managing this <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>We have also experienced a shift in     <font color="blue">customer demand towards</font> our IVIS 200 systems and, more recently, IVIS 50     systems, and we have altered our planned <font color="blue">manufacturing</font> to increase IVIS     <font color="blue">system output</font> in an effort to meet this demand</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">components</font> of our     IVIS 200 systems and IVIS 50 systems are specially <font color="blue">manufacture</font>d by our     single-source suppliers and supply of these parts to us requires adequate     lead time that can result in <font color="blue">production delays</font></td>
    </tr>
    <tr>
      <td>If we experience unexpected     shifts  in  customer  demand  that  requires  <font color="blue">alterations</font>  to  planned     <font color="blue">manufacturing</font>, we may experience <font color="blue">production delays</font> that <font color="blue">could restrict</font> our     sales  growth</td>
    </tr>
    <tr>
      <td>If,  following the closing of the <font color="blue">merger with</font> Caliper,     <font color="blue">manufacturing</font>  of our IVIS systems is <font color="blue">relocated away from</font> our Alameda,     California <font color="blue">facility</font>, any <font color="blue">manufacturing</font> delays or <font color="blue"><font color="blue">disruption</font>s</font> relating to the     relocation could <font color="blue">negatively impact</font> our ability to <font color="blue"><font color="blue">meet customer</font> demand</font></td>
    </tr>
    <tr>
      <td>If     we are unable to <font color="blue"><font color="blue">meet customer</font> demand</font> for IVIS Imaging Systems, it would     <font color="blue"><font color="blue">adversely</font> affect</font> our financial results and restrict our <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>We  depend  on a limited number of suppliers, and we will be unable to     <font color="blue">manufacture</font> or deliver our products if <font color="blue">shipments from</font> these suppliers are     <font color="blue">interrupted</font> or are not <font color="blue">supplied on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>We use original equipment <font color="blue">manufacture</font>rs, or OEMs, for various parts of our     IVIS Imaging Systems, including the cameras, boxes, certain subassemblies,     filters and lenses</td>
    </tr>
    <tr>
      <td>We obtain these <font color="blue">key <font color="blue">components</font></font> from a small number of     sources</td>
    </tr>
    <tr>
      <td>For example, the lens for our IVIS 200 system is obtained from a     <font color="blue">single source on</font> a purchase order <font color="blue">basis from</font> Coastal Optical Systems Inc,     and the CCD cameras for all of our IVIS Imaging                                           21     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>Systems are obtained <font color="blue">from two sources</font>, Spectral Instruments, Inc</td>
    </tr>
    <tr>
      <td>We have binding supply <font color="blue"><font color="blue">agreement</font>s</font> with Spectral and     Andor</td>
    </tr>
    <tr>
      <td>From time to time, we have experienced delays in obtaining <font color="blue">components</font>     <font color="blue">from certain</font> of our suppliers, which have had an <font color="blue">impact on</font> our production     schedule for <font color="blue"><font color="blue">imaging system</font>s</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">alternative sources</font> for these     <font color="blue">components</font> in the event of a <font color="blue">disruption</font> or <font color="blue">discontinuation</font> in <font color="blue">supply would</font>     not be <font color="blue">available on</font> a <font color="blue">timely basis</font>, which would disrupt our <font color="blue">operations</font> and     impair our ability to <font color="blue">manufacture</font> and sell our products</td>
    </tr>
    <tr>
      <td>Our  dependence  upon  <font color="blue">outside suppliers</font> and OEMs <font color="blue">exposes us</font> to risks,     including:           •   the <font color="blue">possibility</font> that one or more of our <font color="blue">suppliers could terminate</font>     their <font color="blue">services at</font> any time;           •   the <font color="blue">potential inability</font> of our suppliers to obtain required <font color="blue">components</font>     or products;           •   reduced control over pricing, quality and timely delivery, due to the     <font color="blue">difficult</font>ies in switching to <font color="blue">alternative suppliers</font>;           •   the <font color="blue">potential delays</font> and expense of seeking <font color="blue">alternative suppliers</font>; and           •   increases in prices of raw materials, products and <font color="blue">key <font color="blue">components</font></font></td>
    </tr>
    <tr>
      <td>Because we receive revenue principally from <font color="blue">biomedical research institutions</font>     and <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and <font color="blue">chemical companies</font>, the industry     <font color="blue">conditions</font> faced by those companies and their <font color="blue"><font color="blue">capital spending</font> policies may</font>     have a <font color="blue">significant</font> effect on the demand for our products</td>
    </tr>
    <tr>
      <td>We  market  our products to <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font> and chemical     companies and <font color="blue">biomedical research institutions</font>, and the <font color="blue">capital spending</font>     policies of these entities can have a <font color="blue">significant</font> effect on the demand for     our products</td>
    </tr>
    <tr>
      <td>These policies vary <font color="blue">significant</font>ly between different customers     and  are  based  on a wide variety of factors, including the resources     available for <font color="blue">purchasing research equipment</font>, the <font color="blue">spending priorities among</font>     <font color="blue">various types</font> of <font color="blue">research companies</font> and the policies regarding capital     <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">volatility</font> of the <font color="blue">public stock market</font> for     bio<font color="blue">technology</font> companies has at certain times <font color="blue">significant</font>ly impacted the     ability of these companies to raise capital, which has <font color="blue">directly affected</font>     their <font color="blue">capital spending</font> budgets</td>
    </tr>
    <tr>
      <td>In addition, continued consolidation within     the <font color="blue">pharmaceutical</font> industry will likely delay and <font color="blue">may potentially reduce</font>     capital   spending   by  <font color="blue">pharmaceutical</font>  companies  involved  in  such     <font color="blue">consolidations</font></td>
    </tr>
    <tr>
      <td>During the past several years, many of our customers and     <font color="blue">potential customers</font>, particularly in the bio<font color="blue">pharmaceutical</font> industry, have     reduced their <font color="blue">capital spending</font> budgets because of these <font color="blue">generally adverse</font>     prevailing economic <font color="blue">conditions</font>, consolidation in the industry and increased     <font color="blue">pressure on</font> the <font color="blue">profitability</font> of such companies, due in part to <font color="blue">competition</font>     <font color="blue">from generic drugs</font></td>
    </tr>
    <tr>
      <td>If our customers and <font color="blue">potential customers</font> do not increase     their <font color="blue">capital spending</font> budgets, because of <font color="blue">continuing adverse economic</font>     <font color="blue">conditions</font> or <font color="blue">further consolidation</font> in the industry, we <font color="blue">could face weak</font>     demand for our products</td>
    </tr>
    <tr>
      <td>Similarly, changes in <font color="blue">availability</font> of <font color="blue">grant moneys</font>     may impact our sales to <font color="blue">academic customers</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">development</font>s regarding     <font color="blue">safety issues</font> for <font color="blue">widely used drugs</font>, including actual and/or threatened     <font color="blue">litigation</font>, also may affect <font color="blue">capital spending</font> by <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Any decrease or delay in <font color="blue">capital spending</font> by <font color="blue">life sciences</font> or chemical     companies or biomedical <font color="blue">researchers</font> could cause our revenue to decline and     harm our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, consolidation within the <font color="blue">pharmaceutical</font> industry may not only     <font color="blue">affect demand</font> for our products, but also existing business <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>If     two or more of our present or <font color="blue">future customers merge</font>, we may not receive the     same fees under <font color="blue"><font color="blue">agreement</font>s</font> with the <font color="blue">combined entities</font> that we received under     <font color="blue"><font color="blue">agreement</font>s</font> with these <font color="blue">customers prior</font> to their merger</td>
    </tr>
    <tr>
      <td>Moreover, if one of     our customers merges with an entity that is not a customer, the new combined     entity <font color="blue">may prematurely terminate</font> our <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">development</font>s     could <font color="blue">materially</font> harm our business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>If we fail to <font color="blue">properly manage</font> our growth, our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">substantially</font> increased the scale of our <font color="blue">operations</font> since our     <font color="blue">initial public offering</font> in 2004</td>
    </tr>
    <tr>
      <td>If we are unable to manage our growth     <font color="blue">effectively</font>, our <font color="blue">losses could increase</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">management</font> of our <font color="blue">growth will</font>     depend, among other things, upon our ability to improve our operational,     financial and <font color="blue">management</font> controls, reporting systems and procedures</td>
    </tr>
    <tr>
      <td>In     addition, we will have to invest in <font color="blue">additional customer support resources</font>,     hire and <font color="blue">train <font color="blue">additional personnel</font></font> for <font color="blue">manufacturing</font>, installation and     field  support,  and expand our inventory of <font color="blue"><font color="blue">instrumentation</font> parts</font> and     <font color="blue">components</font>, which will result in <font color="blue">additional burdens on</font> our systems and     resources and require additional capital <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>We have a limited sales and <font color="blue">marketing <font color="blue">organization</font></font>, and although we intend     to increase our sales and <font color="blue">marketing <font color="blue">organization</font></font>, we may be unable to build     an <font color="blue">organization</font> to meet demand for our products and services</td>
    </tr>
    <tr>
      <td>We currently have a limited number of people in our <font color="blue">sales force</font> engaged in     the <font color="blue">direct sale</font> of our products, many of whom were added in 2004</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>our  products  are  technical in nature, we believe that our sales and     <font color="blue">marketing staff must</font> have scientific or <font color="blue">technical expertise</font> and experience     and require they be trained in the <font color="blue">instrumentation</font> and reagents that they     sell</td>
    </tr>
    <tr>
      <td>Although we expanded our sales and <font color="blue">marketing <font color="blue">organization</font></font> in 2004 and     continued our <font color="blue">expansion efforts</font> in 2005, the number of <font color="blue">employees with</font> these     skills is <font color="blue">relatively</font> small</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is intense and we may not be able to     continue to attract and retain <font color="blue">sufficient qualified</font> people or grow and     maintain an <font color="blue">efficient</font> and <font color="blue">effective sales</font> and marketing department</td>
    </tr>
    <tr>
      <td>In     several foreign countries and <font color="blue">regions outside</font> the US, including several     countries in Europe and Asia, we sell our products and <font color="blue">services primarily</font>     through  third-party distributors</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> the sales and     <font color="blue">marketing efforts</font> of our third-party distributors in these <font color="blue">international</font>     markets</td>
    </tr>
    <tr>
      <td>These <font color="blue">distributors may</font> not commit the <font color="blue"><font color="blue">necessary</font> resources</font> to     <font color="blue">effectively</font> market and sell our products and services</td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial condition</font>     would be harmed if we fail to build an <font color="blue">adequate direct</font> and in<font color="blue">direct sale</font>s     and  marketing  <font color="blue">organization</font>  and  our marketing and <font color="blue">sales efforts</font> are     <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on key employees</font> in a <font color="blue">competitive market</font> for <font color="blue">skilled personnel</font>,     and <font color="blue">without additional employees</font>, we <font color="blue">cannot grow</font> or achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> team,     including  David  W Carter, chairman of our board and <font color="blue">chief executive</font>     officer, and Pamela R Contag, Ph</td>
    </tr>
    <tr>
      <td><font color="blue">Carter and Dr</font></td>
    </tr>
    <tr>
      <td>Contag, we do not have any key person <font color="blue">life insurance on</font>     <font color="blue">such individuals</font></td>
    </tr>
    <tr>
      <td>Additionally, while we have change of <font color="blue">control severance</font>     <font color="blue">arrangements</font> in place for the <font color="blue">principal members</font> of our <font color="blue">management</font> team, as a     practical matter, such <font color="blue">arrangements</font> may not ensure the employee’s retention</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success also will depend</font> in part on the <font color="blue">continued service</font> of our     key scientific, consulting and <font color="blue">management</font> personnel and our ability to     identify  hire  and retain <font color="blue">additional personnel</font></td>
    </tr>
    <tr>
      <td>We experience intense     <font color="blue">competition</font> for <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may be unable to attract and retain     personnel  <font color="blue">necessary</font>  for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>Moreover, a     <font color="blue">significant</font> portion of our work force is located in the San Francisco Bay     Area of California, where demand for <font color="blue">personnel with</font> the scientific and     <font color="blue">technical skills</font> we seek is <font color="blue">extremely high</font> and is likely to <font color="blue">remain high</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Our <font color="blue"><font color="blue">intellectual property</font> rights</font>, including one patent that is due to expire     in 2006, may not <font color="blue">provide meaningful commercial protection</font> for our products,     <font color="blue">which could enable third parties</font> to use our <font color="blue">technology</font>, or very similar     <font color="blue">technology</font>, and <font color="blue">could reduce</font> our ability to compete in the market</td>
    </tr>
    <tr>
      <td>We rely on patent, copyright, trade secret and <font color="blue">trademark laws</font> to limit the     ability of others to <font color="blue">compete with us using</font> the same or similar <font color="blue">technology</font> in     the  US and other countries</td>
    </tr>
    <tr>
      <td>However, these <font color="blue">laws afford only</font> limited     protection and may not <font color="blue">adequately protect</font> our rights to the extent <font color="blue">necessary</font>     to sustain any <font color="blue">competitive advantage</font> we may have</td>
    </tr>
    <tr>
      <td>The laws of some foreign     countries do not <font color="blue">protect <font color="blue">proprietary</font> rights</font> to the <font color="blue">same extent as</font> the laws     of the US, and many companies have <font color="blue">encountered</font> <font color="blue">significant</font> problems in     protecting their <font color="blue">proprietary</font> rights abroad</td>
    </tr>
    <tr>
      <td>These problems can be caused by     the  absence of <font color="blue">adequate rules</font> and methods for defending and enforcing     <font color="blue"><font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>We will be able to protect our <font color="blue">technology</font> from unauthorized use by third     <font color="blue">parties only</font> to the extent that they are <font color="blue">covered by valid</font> and enforceable     patents or are <font color="blue">effectively</font> maintained <font color="blue">as trade secrets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font>     of companies developing tools for <font color="blue">pharmaceutical</font>, bio<font color="blue">technology</font>, biomedical     and  <font color="blue">chemical industries</font>, including our patent position, generally are     uncertain and <font color="blue">involve complex legal</font> and factual questions, particularly as     to <font color="blue">questions concerning</font> the <font color="blue">enforceability</font> of <font color="blue">such patents against</font> alleged     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> patent situation outside the US is even     more uncertain, particularly with respect to the <font color="blue">patentability</font> of transgenic     animals</td>
    </tr>
    <tr>
      <td>Changes in either the patent laws or in <font color="blue">interpretations</font> of patent     laws in the US and other <font color="blue">countries may therefore diminish</font> the value of our     <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>Moreover, our patents and patent <font color="blue">application</font>s may not     be <font color="blue">sufficiently broad</font> to <font color="blue">prevent others from practicing</font> our <font color="blue">technologies</font> or     from developing <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>We also face the risk that <font color="blue">others may</font>     <font color="blue">independently</font> develop similar or alternative <font color="blue">technologies</font> or <font color="blue">design around</font>     our patented <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We own, or <font color="blue">control through licenses</font>, a variety of <font color="blue">issued patents</font> and pending     patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>However, the patents on which we rely may be challenged     and  invalidated, and our patent <font color="blue">application</font>s may not result in issued     patents</td>
    </tr>
    <tr>
      <td>AntiCancer, a party with whom we have been engaged in ongoing     commercial <font color="blue">litigation</font>, filed a lawsuit against us alleging <font color="blue">infringement</font> of     five  patents and requesting that the court declare invalid one of our     primary patents covering methods of in <font color="blue">vivo <font color="blue">biophotonic</font></font> imaging</td>
    </tr>
  </tbody>
</table>